Table 1 Baseline clinico-pathologic characteristics of patients with pure LCNEC in Cohorts 1 and 2
From: Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
Cohort 1 | Cohort 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Clinical characteristic | LCNEC Total (N = 217) | SCLC-like LCNEC (N = 19) | NSCLC-like LCNEC (N = 25) | Unclassified (N = 41) | Unknown (N = 132) | LCNEC Total (N = 373) | SCLC-like LCNEC (N = 136) | NSCLC-like LCNEC (N = 89) | Unclassified (N = 148) |
Agea (Median, IQR) | 66 (59–71) | 69 (53–70) | 63 (57–72) | 63 (52–70) | 67 (61–72) | 67 (38–89) | 68 (38–89) | 63 (45–83) | 69 (40–88) |
Sex | |||||||||
Females | 97 (45%) | 10 (53%) | 15 (60%) | 16 (39%) | 56 (42%) | 175 (47%) | 72 (53%) | 45 (51%) | 67 (45%) |
Males | 120 (55%) | 9 (47%) | 10 (40%) | 25 (61%) | 76 (58%) | 198 (53%) | 64 (47%) | 44 (49%) | 81 (55%) |
Not reportedb | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Race | |||||||||
Asian | 7 (3.4%) | 1 (5.6%) | 2 (8.3%) | 2 (5.1%) | 2 (1.6%) | 7 (2.3%) | 2 (1.8%) | 0 (0%) | 5 (4%) |
Black | 28 (13.5%) | 1 (5.6%) | 2 (8.3%) | 4 (10%) | 21 (17%) | 48 (16%) | 15 (13%) | 9 (13%) | 24 (19%) |
White | 168 (81%) | 15 (83%) | 18 (75) | 33 (85%) | 102 (80%) | 238 (77%) | 92 (82%) | 57 (81%) | 89 (71%) |
Other | 5 (2.4%) | 1 (5.6%) | 2 (8.3%) | 0 (0%) | 2 (1.6%) | 15 (4.9%) | 3 (2.7%) | 4 (5.7%) | 8 (6.3%) |
Not reportedb | 9 | 1 | 1 | 2 | 5 | 65 | 24 | 19 | 22 |
PD-L1 TPS | |||||||||
<1% | 91 (68%) | 9 (64%) | 11 (85%) | 22 (69%) | 49 (65%) | 269 (75%) | 98 (75%) | 64 (77%) | 107 (75%) |
1–49% | 37 (28%) | 4 (29%) | 2 (15%) | 7 (22%) | 24 (32%) | 67 (19%) | 27 (21%) | 14 (17%) | 26 (18%) |
≥50% | 6 (4%) | 1 (7%) | 0 (0%) | 3 (9%) | 2 (3%) | 20 (5.5%) | 6 (4.6%) | 5 (6%) | 9 (6.3%) |
Not reportedb | 83 | 5 | 12 | 9 | 57 | 13 | 5 | 6 | 6 |
1st line systemic treatment category | |||||||||
Chemotherapy | 121 (56%) | 8 (42%) | 12 (48%) | 23 (56%) | 78 (59%) | 46 (32%) | 18 (31%) | 13 (33%) | 15 (31%) |
Chemoimmunotherapy | 82 (38%) | 11 (58%) | 11 (44%) | 13 (32%) | 47 (36%) | 88 (60%) | 35 (60.3%) | 22 (56%) | 31 (63%) |
Immunotherapy | 14 (6%) | 0 (0%) | 2 (8%) | 5 (12%) | 7 (5%) | 12 (8.3%) | 5 (8.6%) | 4 (10%) | 3 (6.1%) |
Not reportedb | 227 | 78 | 50 | 99 | |||||
